Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Nihon Yakurigaku Zasshi ; 155(3): 145-148, 2020.
Article in Japanese | MEDLINE | ID: mdl-32378631

ABSTRACT

Alcohol dependence is one of the psychiatric disorders affecting over 1 million people in Japan. Mesolimbic dopamine neuron projecting from ventral tegmental area to nucleus accumbens (Reward system) plays important roles in alcohol dependence including other dependence. Accumulating evidence indicates that the endogenous opioid system regulate this reward system. That is, alcohol stimulates the release of endogenous opioid peptides such as ß-endorphin and dynorphin in the brain. ß-endorphin activates µ-opioid receptor leading to euphoric mood and positive reinforcement, while dynorphin activates κ-opioid receptor leading to dysphoric mood and negative reinforcement. These euphoric/dysphoric mood and reinforcement effects via endogenous opioid systems are suggested to be implicated in repeated alcohol intake in patients with alcohol dependence. Nalmefene acts as an antagonist at µ- and δ-opioid receptor and a partial agonist at κ-opioid receptor. Preclinical studies have shown that nalmefene reduced the alcohol intake in alcohol preference rats. In clinical trials, as-needed use of nalmefene with psychosocial support reduced the number of heavy-drinking days and total alcohol consumption. These results suggest that nalmefene modulates the alcohol-induced euphoric/dysphoric mood via opioid system and thereby contribute to reduction in alcohol consumption in patients with alcohol dependence. Here, we summarize the implications of opioid system in alcohol dependence and pharmacological profiles of nalmefene in preclinical and clinical studies.


Subject(s)
Alcoholism/drug therapy , Naltrexone/analogs & derivatives , Narcotic Antagonists/pharmacology , Receptors, Opioid/agonists , Animals , Clinical Trials as Topic , Humans , Japan , Naltrexone/pharmacology , Rats
2.
Neuropsychopharmacol Rep ; 39(4): 279-288, 2019 12.
Article in English | MEDLINE | ID: mdl-31487433

ABSTRACT

BACKGROUND: Long-term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D2 receptor sensitization. We evaluated the effects of brexpiprazole on D2 receptor sensitivity after subchronic treatment in rats. We also evaluated whether brexpiprazole could suppress enhanced response to D2 receptors in rats subchronically dosed with another atypical antipsychotic. METHODS: The maximum D2 receptor density (Bmax ) and apomorphine (a D2 receptor agonist)-induced stereotypy were measured in rats orally dosed with vehicle, haloperidol (1 mg/kg), or brexpiprazole (4 or 30 mg/kg for Bmax , 6 or 30 mg/kg for stereotypy) for 21 days. Then, effects of oral administrations of brexpiprazole (3 mg/kg), aripiprazole (10 mg/kg), and olanzapine (3 mg/kg) against increases in apomorphine-induced hyperlocomotion and (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI: a 5-HT2A receptor agonist)-induced head twitches were evaluated in rats subcutaneously treated with risperidone (1.5 mg/kg/d) via minipumps for 21 days. RESULTS: Haloperidol and brexpiprazole (30 mg/kg: approximately tenfold ED50 of anti-apomorphine-induced stereotypy) but not brexpiprazole (4 or 6 mg/kg) significantly increased the Bmax and apomorphine-induced stereotypy. Brexpiprazole (3 mg/kg) and olanzapine (3 mg/kg) significantly suppressed both increases in apomorphine-induced hyperlocomotion and also DOI-induced head twitches in rats subchronically treated with risperidone, but aripiprazole (10 mg/kg) significantly suppressed only apomorphine-induced hyperlocomotion. CONCLUSION: Brexpiprazole has a low risk of D2 receptor sensitization after a repeated administration and suppresses the rebound phenomena related to D2 and 5-HT2A receptors after a repeated administration of risperidone.


Subject(s)
Antipsychotic Agents/pharmacology , Dyskinesia, Drug-Induced/metabolism , Quinolones/pharmacology , Receptor, Serotonin, 5-HT2A/metabolism , Receptors, Dopamine D2/metabolism , Stereotyped Behavior/drug effects , Thiophenes/pharmacology , Animals , Antipsychotic Agents/adverse effects , Apomorphine/pharmacology , Dopamine Agonists/pharmacology , Haloperidol/pharmacology , Rats
3.
Pharmacol Biochem Behav ; 177: 61-68, 2019 02.
Article in English | MEDLINE | ID: mdl-30629965

ABSTRACT

Although epidemiological data suggest that repeated use of cannabis during adolescence may increase the risk for psychosis, its precise molecular mechanisms remain undetermined. In this study, we examined whether brain-derived neurotrophic factor (BDNF) and its receptor TrkB signaling plays a role in the risk for psychosis after exposure of cannabinoid (CB) receptor agonist during adolescence. Repeated administration of the CB receptor agonist WIN55,212-2 (2 mg/kg/day) during adolescence (P35 - P45) significantly increased methamphetamine (METH: 1 mg/kg)-induced hyperlocomotion in adulthood (P70 - P74) compared with vehicle-treated mice. Western blot analysis showed that BDNF-TrkB signaling in the nucleus accumbens (NAc) of WIN55,212-2-treated mice were significantly higher than that of vehicle-treated mice. Interestingly, an increase in the METH-induced locomotion in WIN55,212-2-treated mice was significantly attenuated by subsequent repeated administration of the TrkB antagonist ANA-12 (0.5 mg/kg/day from P70 to P83). Furthermore, increased BDNF-TrkB signaling in the NAc from WIN55,212-2-treated mice was also significantly attenuated after subsequent repeated administration of ANA-12. These findings suggest that increased BDNF-TrkB signaling in the NAc plays an important role in the increase in METH-induced locomotion in adulthood after repeated WIN55,212-2 administration during adolescence. Therefore, TrkB antagonists would be potential prophylactic and therapeutic drugs for psychosis in adult with cannabis use during adolescence.


Subject(s)
Benzoxazines/pharmacology , Brain-Derived Neurotrophic Factor/metabolism , Cannabinoid Receptor Agonists/pharmacology , Marijuana Abuse/metabolism , Membrane Glycoproteins/metabolism , Morpholines/pharmacology , Naphthalenes/pharmacology , Nucleus Accumbens/metabolism , Protein-Tyrosine Kinases/metabolism , Psychoses, Substance-Induced/pathology , Animals , Azepines/pharmacology , Behavior, Animal/drug effects , Benzamides/pharmacology , Benzoxazines/administration & dosage , Cannabinoid Receptor Agonists/administration & dosage , Cannabinoids/pharmacology , Cannabis/chemistry , Central Nervous System Stimulants/pharmacology , Dentate Gyrus/metabolism , Locomotion/drug effects , Male , Membrane Glycoproteins/antagonists & inhibitors , Methamphetamine/pharmacology , Mice , Mice, Inbred C57BL , Morpholines/administration & dosage , Naphthalenes/administration & dosage , Prefrontal Cortex/metabolism , Protein-Tyrosine Kinases/antagonists & inhibitors , Risk
4.
Psychopharmacology (Berl) ; 234(21): 3165-3173, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28748374

ABSTRACT

RATIONALE: Brexpiprazole, a serotonin-dopamine activity modulator, is approved in the USA as an adjunctive therapy to antidepressants for treating major depressive disorders. Similar to the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine, the combination of brexpiprazole and fluoxetine has demonstrated antidepressant-like effects in animal models of depression. OBJECTIVES: The present study was conducted to examine whether the combination of brexpiprazole and fluoxetine could affect the tissue levels of amino acids [glutamate, glutamine, γ-aminobutyric acid (GABA), D-serine, L-serine, and glycine] that are associated with NMDAR neurotransmission. METHODS: The tissue levels of amino acids in the frontal cortex, striatum, hippocampus, and cerebellum were measured after a single [or repeated (14 days)] oral administration of vehicle, fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or a combination of the two drugs. Furthermore, we measured the tissue levels of amino acids after a single administration of the NMDAR antagonist (R)-ketamine. RESULTS: A single injection of the combination of fluoxetine and brexpiprazole significantly increased GABA levels in the striatum, the D-serine/L-serine ratio in the frontal cortex, and the glycine/L-serine ratio in the hippocampus. A repeated administration of the combination significantly altered the tissue levels of amino acids in all regions. Interestingly, a repeated administration of the combination significantly decreased the D-serine/L-serine ratio in the frontal cortex, striatum, and hippocampus. In contrast, a single administration of (R)-ketamine significantly increased the D-serine/L-serine ratio in the frontal cortex. CONCLUSIONS: These results suggested that alterations in the tissue levels of these amino acids may be involved in the antidepressant-like effects of the combination of brexpiprazole and fluoxetine.


Subject(s)
Amino Acids/metabolism , Antidepressive Agents/pharmacology , Brain/drug effects , Fluoxetine/pharmacology , Ketamine/pharmacology , Quinolones/pharmacology , Thiophenes/pharmacology , Administration, Oral , Animals , Depressive Disorder, Major/drug therapy , Male , Mice , Mice, Inbred C57BL , Receptors, N-Methyl-D-Aspartate/drug effects
5.
Psychopharmacology (Berl) ; 234(4): 525-533, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27844095

ABSTRACT

RATIONALE: Addition of low doses of atypical antipsychotic drugs with selective serotonin reuptake inhibitors (SSRIs) could promote a rapid antidepressant effect in treatment-resistant patients with major depression. Brexpiprazole, a new atypical antipsychotic drug, has been used as adjunctive therapy for the treatment of major depression. OBJECTIVES: The present study was undertaken to examine whether brexpiprazole could augment antidepressant effects of the SSRI fluoxetine in an inflammation model of depression. METHODS: We examined the effects of fluoxetine (10 mg/kg), brexpiprazole (0.1 mg/kg), or the combination of the two drugs on depression-like behavior, alterations in the brain-derived neurotrophic factor (BDNF) - TrkB signaling, and dendritic spine density in selected brain regions after administration of lipopolysaccharide (LPS) (0.5 mg/kg). RESULTS: Combination of brexpiprazole and fluoxetine promoted a rapid antidepressant effect in inflammation model although brexpipazole or fluoxetine alone did not show antidepressant effect. Furthermore, the combination significantly improved LPS-induced alterations in the BDNF - TrkB signaling and dendritic spine density in the prefrontal cortex, CA3 and dentate gyrus, and nucleus accumbens. CONCLUSIONS: These results suggest that add-on of brexpiprazole to fluoxetine can produce a rapid antidepressant effect in the LPS inflammation model of depression, indicating that adjunctive therapy of brexpiprazole to SSRIs could produce a rapid antidepressant effect in depressed patients with inflammation.


Subject(s)
Antidepressive Agents/pharmacology , Antipsychotic Agents/pharmacology , Behavior, Animal/drug effects , Dendritic Spines/drug effects , Depression/drug therapy , Fluoxetine/pharmacology , Quinolones/pharmacology , Thiophenes/pharmacology , Animals , Antidepressive Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Brain-Derived Neurotrophic Factor/metabolism , Dendritic Spines/metabolism , Depression/metabolism , Fluoxetine/therapeutic use , Inflammation/drug therapy , Inflammation/metabolism , Male , Mice , Neurons/drug effects , Neurons/metabolism , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Quinolones/therapeutic use , Signal Transduction/drug effects , Thiophenes/therapeutic use
6.
Sci Rep ; 6: 39209, 2016 12 19.
Article in English | MEDLINE | ID: mdl-27991542

ABSTRACT

Addition of low doses of the atypical antipsychotic drug brexpiprazole with selective serotonin reuptake inhibitors (SSRIs) could promote antidepressant effect in patients with major depressive disorder although the precise mechanisms underlying the action of the combination are unknown. Combination of low dose of brexpiprazole (0.1 mg/kg) and SSRI fluoxetine (10 mg/kg) could promote a rapid antidepressant effect in social defeat stress model although brexpiprazole or fluoxetine alone did not show antidepressant effect. Furthermore, the combination significantly improved alterations in the brain-derived neurotrophic factor (BDNF) - TrkB signaling and dendritic spine density in the prefrontal cortex, hippocampus, and nucleus accumbens in the susceptible mice after social defeat stress. Interestingly, TrkB antagonist ANA-12 significantly blocked beneficial effects of combination of brexpiprazole and fluoxetine on depression-like phenotype. These results suggest that BDNF-TrkB signaling plays a role in the rapid antidepressant action of the combination of brexpiprazole and fluoxetine.


Subject(s)
Antidepressive Agents/pharmacology , Fluoxetine/pharmacology , Quinolones/pharmacology , Signal Transduction/drug effects , Thiophenes/pharmacology , Animals , Antidepressive Agents/therapeutic use , Azepines/pharmacology , Behavior, Animal/drug effects , Benzamides/pharmacology , Brain-Derived Neurotrophic Factor/metabolism , Dendritic Spines/drug effects , Dendritic Spines/physiology , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/pathology , Disease Models, Animal , Drug Therapy, Combination , Fluoxetine/therapeutic use , Male , Mice , Mice, Inbred C57BL , Phenotype , Quinolones/therapeutic use , Receptor, trkB/antagonists & inhibitors , Receptor, trkB/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Thiophenes/therapeutic use
7.
Clin Ther ; 37(8): 1632-42, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26243073

ABSTRACT

PURPOSE: Alzheimer disease (AD) is a growing global health and economic issue as elderly populations increase dramatically across the world. Despite the many clinical trials conducted, currently no approved disease-modifying treatment exists. In this commentary, the present status of AD drug development and the grounds for collaborations between government, academia, and industry to accelerate the development of disease-modifying AD therapies are discussed. METHODS: Official government documents, literature, and news releases were surveyed by MEDLINE and website research. FINDINGS: Currently approved anti-AD drugs provide only short-lived symptomatic improvements, which have no effect on the underlying pathogenic mechanisms or progression of the disease. The failure to approve a disease-modifying drug for AD may be because the progression of AD in the patient populations enrolled in clinical studies was too advanced for drugs to demonstrate cognitive and functional improvements. The US Food and Drug Administration and the European Medicines Agency recently published draft guidance for industry which discusses approaches for conducting clinical studies with patients in early AD stages. For successful clinical trials in early-stage AD, however, it will be necessary to identify biomarkers highly correlated with the clinical onset and the longitudinal progress of AD. In addition, because of the high cost and length of clinical AD studies, support in the form of global initiatives and collaborations between government, industry, and academia is needed. IMPLICATIONS: In response to this situation, national guidance and international collaborations have been established. Global initiatives are focusing on 2025 as a goal to provide new treatment options, and early signs of success in biomarker and drug development are already emerging.


Subject(s)
Alzheimer Disease/drug therapy , Clinical Trials as Topic , Drug Approval , Alzheimer Disease/blood , Alzheimer Disease/prevention & control , Biomarkers/blood , Global Health , Humans , Neuroprotective Agents/therapeutic use , Nootropic Agents/therapeutic use , Research Design
8.
Eur Neuropsychopharmacol ; 25(4): 505-11, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25687838

ABSTRACT

Brexpiprazole, a novel atypical antipsychotic drug, is currently being tested in clinical trials for treatment of psychiatric disorders, such as schizophrenia and major depressive disorder. The drug is known to act through a combination of partial agonistic activity at 5-hydroxytryptamine (5-HT)1A, and dopamine D2 receptors, and antagonistic activity at 5-HT2A receptors. Accumulating evidence suggests that antipsychotic drugs act by promoting neurite outgrowth. In this study, we examined whether brexpiprazole affected neurite outgrowth in cell culture. We found that brexpiprazole significantly potentiated nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells, in a concentration dependent manner. The selective 5-HT1A receptor antagonist, WAY-100,635, was able to block the effects of brexpiprazole on neurite outgrowth, unlike the selective dopamine D2 receptor antagonist, raclopride. Furthermore, the selective 5-HT2A receptor antagonist M100907, but not DOI (5-HT2A receptor agonist), significantly potentiated NGF-induced neurite outgrowth. Moreover, xestospongin C and 2-aminoethoxydiphenyl borate (2-APB), both specific inhibitors of inositol 1,4,5-triphosphate (IP3) receptors, significantly blocked the effects of brexpiprazole. These findings suggest that brexpiprazole-induced neurite outgrowth is mediated through 5-HT1A and 5-HT2A receptors, and subsequent Ca(2+) signaling via IP3 receptors.


Subject(s)
Neurites/drug effects , Quinolones/pharmacology , Receptor, Serotonin, 5-HT1A/metabolism , Receptor, Serotonin, 5-HT2A/metabolism , Serotonin Agents/pharmacology , Thiophenes/pharmacology , Animals , Aripiprazole/therapeutic use , Boron Compounds/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , Fluorobenzenes/pharmacology , HSP90 Heat-Shock Proteins/metabolism , Inositol 1,4,5-Trisphosphate Receptors/antagonists & inhibitors , Inositol 1,4,5-Trisphosphate Receptors/metabolism , Macrocyclic Compounds/pharmacology , Nerve Growth Factor , Oxazoles/pharmacology , PC12 Cells , Piperazines/pharmacology , Piperidines/pharmacology , Pyridines/pharmacology , Rats
9.
Pharmacol Biochem Behav ; 124: 245-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24955861

ABSTRACT

Brexpiprazole, a serotonin-dopamine activity modulator, is currently being tested in clinical trials as a new therapy for a number of neuropsychiatric diseases, including schizophrenia and major depressive disorder. Accumulating evidence suggests that 5-hydroxytryptamine (5-HT)1A receptors play a role in cognition. This study was undertaken to examine whether brexpiprazole, a novel drug with 5-HT1A receptor partial agonism, could improve cognitive deficits in mice, induced by repeated administration of the N-methyl-d-aspartate (NMDA) receptor antagonist, phencyclidine (PCP). Subsequent subchronic (14 days) oral administration of brexpiprazole (0.3, 1, or 3mg/kg/day) significantly attenuated PCP (10mg/kg/day for 10 days)-induced cognitive deficits in mice, in a dose-dependent manner. The effects of brexpiprazole (3mg/kg) were significantly antagonized by co-administration of the selective 5-HT1A receptor antagonist, WAY-100,635 (1.0mg/kg), although WAY-100,635 alone was not effective in this model. These findings suggest that brexpiprazole can ameliorate PCP-induced cognitive deficits in mice via 5-HT1A receptors. Therefore, brexpiprazole could ameliorate cognitive deficits as seen in schizophrenia and other neuropsychiatric diseases.


Subject(s)
Cognition Disorders/drug therapy , Phencyclidine/toxicity , Quinolones/pharmacology , Receptor, Serotonin, 5-HT1A/drug effects , Receptors, Dopamine/drug effects , Thiophenes/pharmacology , Animals , Cognition Disorders/chemically induced , Male , Mice , Mice, Inbred ICR , Quinolones/therapeutic use , Thiophenes/therapeutic use
10.
Pharmacol Biochem Behav ; 103(4): 853-9, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23262300

ABSTRACT

Accumulating evidence suggests that inflammation may play a role in the pathophysiology of major depressive disorder (MDD). Antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), possess anti-inflammatory effects in vitro. Here, we examined the effects of SSRIs and SNRIs on lipopolysaccharide (LPS)-induced inflammation and depressive-like behavior in male mice. A single administration of LPS (0.5mg/kg, i.p.) increased serum levels of the pro-inflammatory cytokine, tumor necrosis factor-α (TNFα) and the anti-inflammatory cytokine, interleukin-10 (IL-10) in mice. Pretreatment with SSRIs (fluoxetine and paroxetine), SNRIs (venlafaxine and duloxetine), or 5-hydroxytryptophan (5-HTP), a precursor of serotonin, attenuated LPS-induced increases in TNFα, whereas it increased serum levels of IL-10, in mice treated with LPS. In the tail suspension test (TST), LPS increased the immobility time without affecting spontaneous locomotor activity, suggesting that LPS induced depressive-like behavior in mice. Treatment with fluoxetine (30 mg/kg) or paroxetine (10mg/kg) significantly shortened LPS-induced increases of immobility time. These results suggested that antidepressants exert anti-inflammatory effects in vivo, and that the serotonergic system may partially mediate these effects. In addition, the anti-inflammatory effects of antidepressants may help alleviate the symptoms of LPS-induced depression in mice.


Subject(s)
Antidepressive Agents/therapeutic use , Cytokines/biosynthesis , Depression/drug therapy , Lipopolysaccharides/toxicity , Animals , Antidepressive Agents/pharmacology , Biomarkers/blood , Cytokines/blood , Depression/blood , Depression/chemically induced , Male , Mice , Mice, Inbred BALB C , Motor Activity/drug effects , Motor Activity/physiology , Treatment Outcome , Up-Regulation/drug effects , Up-Regulation/physiology
11.
Biol Pharm Bull ; 32(3): 318-24, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19252271

ABSTRACT

Protection of neurons from neuronal damage and cell death in neurodegenerative disease is a major challenge in neuroscience research. Donepezil, galantamine and tacrine are acetylcholinesterase inhibitors used for the treatment of Alzheimer's disease, and were believed to be symptomatic drugs whose therapeutic effects are achieved by slowing the hydrolysis of acetylcholine at synaptic termini. However, recent accumulated evidence strongly suggests that these acetylcholinesterase inhibitors also possess neuroprotective properties whose mechanism is independent of acetylcholinesterase inhibition. We have shown that acetylcholinesterase inhibitors protect neurons from glutamate-induced neurotoxicity in the primary culture of rat cortical neurons. It was also found that acetylcholinesterase inhibitor treatment induces up-regulation of nicotinic receptor expression levels, a property which may also have some bearing on their therapeutic effects. We next showed that alpha4 and alpha7-nicotinic receptors play important roles in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Our results also demonstrate the important roles of the phosphatidylinositol 3-kinase pathway downstream of nicotinic receptors in protecting neurons from death and up-regulating nicotinic receptors. This review summarizes recent findings on the roles of the nicotinic receptor in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.


Subject(s)
Acetylcholinesterase/physiology , Cholinesterase Inhibitors/pharmacology , Neuroprotective Agents/pharmacology , Receptors, Nicotinic/physiology , Animals , Cells, Cultured , Donepezil , Galantamine/pharmacology , Glutamates/pharmacology , Indans/pharmacology , Neurons/cytology , Neurons/drug effects , Nicotinic Antagonists/pharmacology , Phosphatidylinositol 3-Kinases/physiology , Piperidines/pharmacology , Rats , Receptors, Nicotinic/biosynthesis , Tacrine/pharmacology , Up-Regulation
12.
Eur J Pharmacol ; 590(1-3): 150-6, 2008 Aug 20.
Article in English | MEDLINE | ID: mdl-18585378

ABSTRACT

alpha7-nicotinic acetylcholine receptors are one of the most abundant subtypes of nicotinic receptors in the brain and have been shown to be involved in the neuroprotective effect of donepezil. Recently, we showed that in primary culture of rat cortical neurons, chronic donepezil treatment (10 muM, 4 days) (1) induces the up-regulation of alpha7-nicotinic receptors, (2) enhances the nicotine-induced increase in [Ca(2+)](i) and (3) enhances the sensitivity to the neuroprotective effect of donepezil. Here we demonstrate the involvement of alpha7-nicotinic receptors in these three effects. Concomitant treatment with nicotinic receptor antagonist inhibited the up-regulation of alpha7-nicotinic receptor, enhancement of the increase in [Ca(2+)](i) induced by nicotine, and enhancement of sensitivity to the neuroprotective effect of donepezil. Next, using inhibitors of phosphatidylinositol 3-kinase and mitogen-activated protein kinase signaling pathways, we demonstrate the involvement of these pathways in the up-regulation of alpha7-nicotinic receptors and in making the neurons more sensitive to the neuroprotective effects of donepezil. Concomitant chronic donepezil treatment with inhibitors of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways inhibited nicotinic receptor up-regulation and enhancement of the response to nicotine, and enhanced the sensitivity to donepezil. This study increases understanding of the less-studied mechanism of chronic donepezil treatment-induced nicotinic receptor up-regulation and increased sensitivity to donepezil.


Subject(s)
Indans/pharmacology , Neuroprotective Agents/pharmacology , Piperidines/pharmacology , Receptors, Nicotinic/drug effects , Animals , Cells, Cultured , Donepezil , Flavonoids/pharmacology , MAP Kinase Signaling System/drug effects , Nicotinic Antagonists/pharmacology , Phosphatidylinositol 3-Kinases/physiology , Rats , Rats, Wistar , Receptors, Nicotinic/analysis , Signal Transduction , Up-Regulation , alpha7 Nicotinic Acetylcholine Receptor
13.
J Neurosci Res ; 86(16): 3575-83, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18655200

ABSTRACT

Previously, we showed that in rat cortical neurons, chronic donepezil treatment (10 microM, 4 days) up-regulates nicotinic receptors (nAChR) and makes neurons more sensitive to the neuroprotective effect of donepezil. Here we examined the mechanism of donepezil-induced neuroprotection in neurons chronically treated with donepezil. The mechanism of neuroprotection was examined under different conditions of exposure to glutamate, acute and moderate, that induce cell death associated with necrotic and apoptotic cell death, respectively. Concomitant treatment with antagonists of nAChRs but not muscarinic receptors inhibited donepezil pretreatment-induced neuroprotection against acute glutamate treatment-induced death. Donepezil pretreatment prevented acute glutamate- and ionomycin-induced neurotoxicity, but not S-nitrosocysteine-induced neurotoxicity, suggesting that donepezil protects neurons via nAChR at levels before nitric oxide synthase activation against acute glutamate neurotoxicity. Concomitant treatment with antagonists of nAChR or phosphatidylinositol 3-kinase (PI3K) signaling inhibitors significantly inhibited neuroprotection against moderate glutamate neurotoxicity and decreased the phosphorylation level of Akt. Neuroprotection was also inhibited by treatment with inhibitor of mitogen-activated protein kinase (MAPK) kinase. These results suggest that donepezil protects neurons against moderate glutamate neurotoxicity via nAChR-PI3K-Akt and MAPK signaling pathways. This study provides novel insight into the mechanism of donepezil-induced neuroprotection that involves nAChR up-regulation.


Subject(s)
Cerebral Cortex/drug effects , Cytoprotection/drug effects , Indans/pharmacology , Nerve Degeneration/drug therapy , Neurons/drug effects , Neuroprotective Agents/pharmacology , Piperidines/pharmacology , Animals , Apoptosis/drug effects , Apoptosis/physiology , Cells, Cultured , Cerebral Cortex/metabolism , Cerebral Cortex/physiopathology , Cholinesterase Inhibitors/pharmacology , Cytoprotection/physiology , Donepezil , Enzyme Inhibitors/pharmacology , Glutamic Acid/metabolism , Glutamic Acid/toxicity , Ionomycin/antagonists & inhibitors , Ionophores/antagonists & inhibitors , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Necrosis/drug therapy , Necrosis/physiopathology , Necrosis/prevention & control , Nerve Degeneration/physiopathology , Nerve Degeneration/prevention & control , Neurons/metabolism , Nicotinic Antagonists , Phosphatidylinositol 3-Kinases/metabolism , Phosphoinositide-3 Kinase Inhibitors , Proto-Oncogene Proteins c-akt/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Wistar , Receptors, Nicotinic/drug effects , Receptors, Nicotinic/metabolism , Signal Transduction/drug effects , Signal Transduction/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...